Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant

Early Phase 1CompletedNCT05277623

Ain Shams University60 enrolled

Overview

Postreperfusion syndrome during living liver transplants remains a serious concern for transplant anesthesiologists. This syndrome is responsible for decreases in systemic blood pressure, systemic vascular resistance, and cardiac output and can even lead to cardiac arrest. Delayed graft function and primary graft nonfunction are closely related to postreperfusion syndrome (Therefore, attenuating the syndrome during anesthesia is of great importance.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Liver Transplant Disorder

Interventions

MannitolDRUG

During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg

0.9% normal salineOTHER

the same amount of 0.9% normal saline

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with end-stage liver disease who will undergo living donor transplantation. Exclusion Criteria: * Patients with a history of portopulmonary hypertension. * Hepatopulmonary syndrome. * Cirrhotic cardiomyopathy. * Hepatorenal syndrome types 1 and 2.

Locations (1)

Medicine Ain Shams University

Cairo, Egypt

Outcomes

Primary Outcomes

mean arterial blood pressure

postreperfusion mean blood pressure

Time frame: one hour after reperfusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.